2017
DOI: 10.1186/s13075-017-1306-0
|View full text |Cite
|
Sign up to set email alerts
|

B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients

Abstract: BackgroundB cell depletion with rituximab (RTX) is approved for treatment of rheumatoid arthritis (RA) and ANCA-associated vasculitides (AAV). Recently, RTX has been shown to be effective in AAV maintenance therapy, but an optimal RTX treatment schedule is unknown and the time to B cell repopulation after RTX has not been studied.MethodsRetrospective single-center analysis of B cell repopulation in patients with AAV, RA or connective tissue disease (CTD) treated with RTX.ResultsBeginning B cell repopulation wi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
63
1
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 92 publications
(70 citation statements)
references
References 22 publications
5
63
1
1
Order By: Relevance
“…Hypogammaglobulinaemia following B cell depletion therapy or targeting of B cell growth factors is common, occurring in 30-56% of patients with AAV after rituximab treatment (173,174), and in up 2% of patients with SLE in the first year of belimumab therapy with levels falling by a median of 13% after 4 years of treatment (175). Total dose exposure of rituximab therapy may not predict hypogammaglobulinaemia, as this effect is more likely to be related to the duration of B cell depletion (174).…”
Section: [H2] Kidney Transplantationmentioning
confidence: 99%
“…Hypogammaglobulinaemia following B cell depletion therapy or targeting of B cell growth factors is common, occurring in 30-56% of patients with AAV after rituximab treatment (173,174), and in up 2% of patients with SLE in the first year of belimumab therapy with levels falling by a median of 13% after 4 years of treatment (175). Total dose exposure of rituximab therapy may not predict hypogammaglobulinaemia, as this effect is more likely to be related to the duration of B cell depletion (174).…”
Section: [H2] Kidney Transplantationmentioning
confidence: 99%
“…As AAV frequently relapses, repeated RTX infusions are used as maintenance treatment. However, as RTX induces a long-lasting depletion of B-cells, it has been associated with an altered B-cell maturation capacity (31). Furthermore, prolonged B-cell depletion may lead to decreased antibody production, as assessed by two retrospective studies in which severe infections and hypogammaglobulinemia were frequent adverse events (26,27).…”
Section: Discussionmentioning
confidence: 99%
“…To test the potential use of CD3-(CD56 or CD16)+ NK cell percentages and counts as disease activity biomarker in ANCA-associated vasculitis, we retrospectively analyzed existing lymphocyte subset data from two German vasculitis centers [24]. Lymphocyte subpopulations phenotyping…”
Section: Methodsmentioning
confidence: 99%